Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TP53 mutations and rituximab-CHOP.

Blood - 8 Nov 2012

Gisselbrecht Christian

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclophosphamide
Share to Doxorubicin
Share to Lymphoma, Large B-Cell, Diffuse
Share to Prednisone

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Rituximab

Share to Vincristine

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Antibodies, Monoclonal, Murine-Derived

Source

Identifiers

PMID: 23144158
DOI: 10.1182/blood-2012-09-455865

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 mutations and rituximab-CHOP.PMID 23144158Read ↗

TP53 mutations in MCL: more therapy is not better.Semantic proximity Read ↗

TP53 mutation and survival in aggressive B cell lymphoma.Semantic proximity Read ↗

[Resistance to rituximab and CD20 mutation].Semantic proximity Read ↗

Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.Semantic proximity Read ↗

Haematological cancer: TP53 mutations sensitize to decitabine.Semantic proximity Read ↗

Gains of MYC locus and outcome in patients with diffuse large B‐cell lymphoma treated with R‐CHOPSemantic proximity Read ↗

Outcomes of Wild Type and TP53-Mutated B Cell Malignancy Patients Receiving CAR-T Cell Therapy: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.Semantic proximity Read ↗

p53 in hematologic malignancies.Semantic proximity Read ↗

Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.Semantic proximity Read ↗

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.Semantic proximity Read ↗

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.